# US 2013/0280266 A1 · Antibodies to il-6 and their uses

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0280266 A1
- Document ID: US20130280266A1
- Status: Published application
- Kind: A1
- Application number: 13/857,867
- Filed: 2013-04-05
- Published: 2013-10-24
- Earliest claimed: 2008-06-18
- Assignees: Bristol-Myers Squibb Company; Pfizer Inc.
- Inventors: Arvind Rajpal; Madhav Narasimha Devalaraja; Kristopher Toy; Lan Yang; Haichun Huang; Jun Z. Zhang; Peter Brams; Brigitte Devaux; David B. Passmore
- Web page: https://patentgrep.com/patent/US20130280266A1

## CPC

- C07K 16/248: {IL-6}
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 13/12: of the kidneys
- A61P 17/06: Antipsoriatics
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 19/08: for bone diseases, e.g. rachitism, Paget's disease
- A61P 19/10: for osteoporosis
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/04: Centrally acting analgesics, e.g. opioids
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 31/04: Antibacterial agents
- A61P 35/00: Antineoplastic agents
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 37/02: Immunomodulators
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14)
- A61K 2039/505: {comprising antibodies}
- C07K 2317/21: from primates, e.g. man
- C07K 2317/56: variable (Fv) region, i.e. VH and/or VL
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/567: Framework region [FR]
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Antibodies and antigen-binding portions thereof that bind to human IL-6 are provided. Also provided are nucleic acids encoding such antibodies and antigen binding portions, methods of making such antibodies and antigen binding portions, compositions comprising such antibodies or antigen binding portions, and uses of such antibodies or antigen binding portions.

## Claims

### Claim 1

An isolated human monoclonal antibody of antigen-binding portion thereof comprising a heavy chain variable (VH) domain amino acid sequence comprising a CDR1, CDR2, and CDR3 region selected from the group consisting of:
a) a VH CDR1 as set forth in SEQ ID NO:5, a VH CDR2 as set forth in SEQ ID NO:6, and a VH CDR3 as set forth in SEQ ID NO:7;
b) a VH CDR1 as set forth in SEQ ID NO:35, a VH CDR2 as set forth in SEQ ID NO:6, and a VH CDR3 as set forth in SEQ ID NO:7;
c) a VH CDR1 as set forth in SEQ ID NO:5, a VH CDR2 as set forth in SEQ ID NO:6, and a VH CDR3 as set forth in SEQ ID NO:41;
d) a VH CDR1 as set forth in SEQ ID NO:5, a VH CDR2 as set forth in SEQ ID NO:6, and a VH CDR3 as set forth in SEQ ID NO:44; and
e) a VH CDR1 as set forth in SEQ ID NO:5, a VH CDR2 as set forth in SEQ ID NO:6, and a VH CDR3 as set forth in SEQ ID NO:45;
wherein said antibody binds specifically to human IL-6.

### Claim 2 (depends on 1)

The isolated human antibody or antigen-binding portion according to claim 1 further comprising a light chain variable (VL) domain amino acid sequence comprising a VL CDR1 as set forth in SEQ ID NO:16, a VL CDR2 as set forth in SEQ ID NO:17, and a VL CDR3 as set forth in SEQ ID NO:18.

### Claim 3

An isolated human antibody or antigen-binding portion thereof comprising a light chain variable (VL) domain amino acid sequence comprising a VL CDR 1 as set forth in SEQ ID NO:16, a VL CDR2 as set forth in SEQ ID NO:17, and a VL CDR3 as set forth in SEQ ID NO:18; wherein said antibody binds specifically to human IL-6.

### Claim 4 (depends on 2)

The isolated antibody or antigen-binding portion thereof according to claim 2 comprising: a VH CDR1 as set forth in SEQ ID NO:5, a VH CDR2 as set forth in SEQ ID NO:6, a VH CDR3 as set forth in SEQ ID NO:7, a VL CDR1 as set forth in SEQ ID NO:16, a VL CDR2 as set forth in SEQ ID NO:17, and a VL CDR3 as set forth in SEQ ID NO:18.

### Claim 5

An isolated human monoclonal antibody or antigen-binding portion thereof comprising a heavy chain variable (VH) domain amino acid sequence selected from the group consisting of SEQ ID NO:4, SEQ ID NO:29, SEQ ID NO:34, SEQ ID NO:37 and SEQ ID NO:40 or differs from any one of SEQ ID NO:4, SEQ ID NO:29, SEQ ID NO:34, SEQ ID NO:37 and SEQ ID NO:40 by having at least one conservative amino acid substitution or differs from any one of SEQ ID NO:4, SEQ ID NO:29, SEQ ID NO:34 SEQ ID NO:37 and SEQ ID NO:40 by having at least one germline amino acid substitution compared to SEQ ID NO:46; wherein said antibody binds specifically to human IL-6.

### Claim 6 (depends on 5)

The antibody or antigen-binding portion thereof according to claim 5, wherein the VH domain is at least 90% identical in amino acid sequence to any one of SEQ ID NO:4, SEQ ID NO:29, SEQ ID NO:34, SEQ ID NO:37 and SEQ ID NO:40.

### Claim 7

An isolated human monoclonal antibody or antigen-binding portion thereof comprising a light chain variable (VL) domain amino acid sequence selected from the group consisting of SEQ ID NO:15 or differs from SEQ ID NO:15, by having a conservative amino acid substitution, or differs from SEQ ID NO:15, by having a germline amino acid substitution compared to SEQ ID NO:47; wherein said antibody binds specifically to human IL-6.

### Claim 8 (depends on 7)

The antibody or antigen-binding portion thereof according to claim 7, comprising a VL domain that is at least 90% identical in amino acid sequence to SEQ ID NO:15.

### Claim 9 (depends on 5)

The isolated human monoclonal antibody or antigen-binding portion thereof according to claim 5 further comprising a light chain variable (VL) domain amino acid sequence selected from the group consisting of SEQ ID NO:15 or differs from SEQ ID NO:15, by having a conservative amino acid substitution, or differs from SEQ ID NO:15 by having a germline amino acid substitution compared to their respective germline sequence selected from the group consisting of SEQ ID NO:47.

### Claim 10

An isolated human monoclonal antibody or antigen-binding portion thereof comprising VL and VH domains at least 90% identical in amino acid sequence to the VL and VH domains, respectively, of antibody 9C8, 9C8 N68T T83S, 9C8 E31G N68T T83S, 9C8 I24V N68T T83S, and 22B5; wherein said antibody binds specifically to human IL-6.

### Claim 11

An isolated human monoclonal antibody or antigen-binding portion thereof comprising:
a) at least one heavy chain CDR1, CDR2 and/or CDR3 independently selected from the heavy chain of an antibody selected from the group consisting of monoclonal antibodies 9C8 IgG1, 9C8 IgG2, 9C8 N68T T83S IgG1, 9C8 N68T T83S IgG2, 9C8 E31G N68T T83S IgG1, 9C8 E31G N68T T83S IgG2, 9C8 I124V N68T T83S IgG1, 9C8 I124V N68T T83S IgG2 and 22B5 IgG1; or
b) at least one light chain CDR1, CDR2 and/or CDR3 independently selected from the light chain of an antibody selected from the group consisting of monoclonal antibodies 9C8 IgG1, 9C8 IgG2, 9C8 N68T T83S IgG1, 9C8 N68T T83S IgG2, 9C8 E31G N68T T83S IgG1, 9C8 E31G N68T T83S IgG2, 9C8 I124V N68T T83S IgG1, 9C8 I124V N68T T83S IgG2 and 22B5 IgG1; or
c) at least a heavy chain CDR1, CDR2 and/or CDR3 independently selected from the heavy chain of an antibody selected from the group consisting of monoclonal antibodies 9C8 IgG1, 9C8 IgG2, 9C8 N68T T83S IgG1, 9C8 N68T T83S IgG2, 9C8 E31G N68T T83S IgG1, 9C8 E31G N68T T83S IgG2, 9C8 I124V N68T T83S IgG1, 9C8 I124V N68T T83S IgG2 and 22B5 IgG1 and at least one light chain CDR1, CDR2 and/or CDR3 independently selected from the light chain of an antibody selected from the group consisting of monoclonal antibodies 9C8 IgG1, 9C8 IgG2, 9C8 N68T T83S IgG1, 9C8 N68T T83S IgG2, 9C8 E31G N68T T83S IgG1, 9C8 E31G N68T T83S IgG2, 9C8 I124V N68T T83S IgG1, 9C8 I124V N68T T83S IgG2 and 22B5 IgG1; wherein said antibody binds specifically to human IL-6.

### Claim 12

An isolated human monoclonal antibody or antigen binding portion thereof comprising a heavy chain having an amino sequence selected from the group consisting of SEQ ID NO:3, SEQ ID NO:24, SEQ ID NO:28, and SEQ ID NO:32, or differs from any one of SEQ ID NO:3, SEQ ID NO:24, SEQ ID NO:28, and SEQ ID NO:32, by having a conservative amino acid substitution, or differs from any one of SEQ ID NO:3, SEQ ID NO:24, SEQ ID NO:28, and SEQ ID NO:32, by having a germline amino acid substitution compared to their respective germline sequence selected from the group consisting of SEQ ID NO:46; wherein said antibody binds specifically to human IL-6.

### Claim 13

An isolated human monoclonal antibody or antigen binding portion thereof comprising a light chain having an amino sequence selected from the group consisting of SEQ ID NO:14, SEQ ID NO:26 and SEQ ID NO:43, or differs from any one of SEQ ID NO:14, SEQ ID NO:26 and SEQ ID NO:43 by having a conservative amino acid substitution, or differs from any one of SEQ ID NO:14, SEQ ID NO:26 and SEQ ID NO:43 by having a germline amino acid substitution compared to the corresponding germline sequence selected from the group consisting of SEQ ID NO:47; wherein said antibody binds specifically to human IL-6.

### Claim 14

An isolated human monoclonal antibody or antigen binding portion thereof comprising a heavy chain and a tight chain selected from the group consisting of:
a) the heavy chain having an amino acid sequence of SEQ ID NO:3 and the light chain having an amino acid sequence of SEQ ID NO:14;
b) the heavy chain having an amino acid sequence of SEQ ID NO:24 and the light chain having an amino acid sequence of SEQ ID NO:26;
c) the heavy chain having an amino acid sequence of SEQ ID NO:28 and the light chain having an amino acid sequence of SEQ ID NO:26; and
d) the heavy chain having an amino acid sequence of SEQ ID NO:31 and the light chain having an amino acid sequence of SEQ ID NO: 14.

### Claim 15 (depends on 14)

The isolated human monoclonal antibody or antigen binding portion thereof according to claim 14 wherein the heavy chain amino acid sequence is SEQ ID NO:28 and the light chain amino acid sequence is SEQ ID NO:26.

### Claim 16 (depends on 1)

The isolated monoclonal antibody or an antigen-binding portion thereof according to claim 1, further comprising or more or VH FR1, FR2, FR3 or FR4 and/or VL FR1, FR2, FR3 or FR4 amino acid sequence of an antibody selected from the group consisting of: 9C8, 9C8 N68T T835, 9C8 E31G N68T T83S, 9C8 I124V N68T T83S, and 22B5.

### Claim 17 (depends on 1)

A pharmaceutical composition comprising the antibody or antigen-binding portion according to claim 1 and a pharmaceutically acceptable carrier.

### Claim 18 (depends on 2)

An isolated cell line, that produces the antibody or antigen-binding portion according to claim 2 or the heavy chain or light chain of said antibody or said antigen-binding portion.

### Claim 19 (depends on 1)

An isolated nucleic acid molecule comprising a nucleotide sequence that encodes an antibody according to claim 1.

### Claim 20 (depends on 19)

A vector comprising the nucleic acid molecule according to claim 19, wherein the vector optionally comprises an expression control sequence operably linked to the nucleic acid molecule.

### Claim 21 (depends on 20)

A host cell comprising the vector according to claim 20.

### Claim 22 (depends on 19)

A host cell comprising the nucleic acid molecule according to claim 19.

### Claim 23 (depends on 1)

A method for treating, preventing or alleviating the symptoms of a IL-6 mediated disorder in a subject in need thereof, comprising administering to said subject an antibody or antigen-binding portion according to claim 1.

### Claim 24 (depends on 17)

A method for treating, preventing or alleviating the symptoms of a IL-6 mediated disorder in a subject in need thereof, comprising administering to said subject the pharmaceutical composition according to claim 17.

### Claim 25 (depends on 23)

The method of claim 23, wherein the subject is afflicted with one or more conditions or disorders selected from the group consisting of an inflammatory disorder, an allergic disorder, an autoimmune disorder, a graft rejection disorder, atherosclerosis, osteoporosis, neuropathic pain, type 2 diabetes mellitus, chronic obstructive pulmonary disease, multiple sclerosis, sepsis, cancer, and a fibrotic condition.

### Claim 26 (depends on 25)

The method of claim 25 wherein said inflammatory disorder is selected from the group consisting of rheumatoid arthritis, juvenile idiopathic arthritis, osteoarthritis, systemic lupus erythematosus, ankylosing spondylitis, psoriasis, Castleman's disease, Crohn's disease, and adult-onset Still's disease.

### Claim 27 (depends on 25)

The method of claim 25 wherein said fibrotic condition is selected from the group consisting of liver fibrosis, renal fibrosis, and pulmonary fibrosis.

### Claim 28 (depends on 25)

The method of claim 25 wherein said cancer is selected from the group consisting of multiple myeloma, renal cell carcinoma, and Castleman's disease.
